Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients

doi:10.3748/wjg.v18.i29.3910

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 29

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3199)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

339

HTML

2503

Figures (1-2)

198

Tables (1-4)

159

Sum=3199

Aug 7, 2012 (publication date) through Apr 29, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Aug 7, 2012; 18(29): 3910-3916
Published online Aug 7, 2012. doi: 10.3748/wjg.v18.i29.3910

Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients

Shi Chen, Ying-Bo Chen, Yuan-Fang Li, Xing-Yu Feng, Zhi-Wei Zhou, Xiu-Hong Yuan, Chao-Nan Qian

Shi Chen, Ying-Bo Chen, Yuan-Fang Li, Xing-Yu Feng, Zhi-Wei Zhou, Xiu-Hong Yuan, Chao-Nan Qian, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China

Shi Chen, Ying-Bo Chen, Zhi-Wei Zhou, Department of Abdominal Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China

Author contributions: Chen S, Chen YB and Qian CN designed the research; Li YF and Feng XY contributed analytic tools; Chen S, Zhou ZW and Yuan XH analyzed the data; and Chen S, Chen YB and Qian CN wrote the paper.

Supported by Grant from the State Key Program of the National Natural Science Foundation of China, No. 81030043

Correspondence to: Dr. Chao-Nan Qian, MD, PhD, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China. qianchn@sysucc.org.cn

Telephone: +86-20-87343457 Fax: +86-20-87343624

Received: December 30, 2011
Revised: April 17, 2012
Accepted: April 20, 2012
Published online: August 7, 2012

Abstract

AIM: To evaluate pretreatment serum carcinoembryonic antigen (CEA) as a predictor of survival for patients with locally advanced gastric cancer receiving perioperative chemotherapy.

METHODS: We retrospectively studied a cohort of 228 gastric cancer patients who underwent D2 gastrectomy combined with chemotherapy at the Sun Yat-sen University Cancer Center between January 2005 and December 2009. Among them, 168 patients received 6-12 cycles of oxaliplatin-based adjuvant (post-operative) chemotherapy, while 60 received perioperative chemotherapy (2 cycles of FOLFOX6 or XELOX before surgery and 4-10 cycles after surgery). Serum CEA was measured using an enzyme immunoassay. The follow-up lasted until December 2010.

RESULTS: In the group that had elevated serum CEA, the difference in survival time between patients receiving perioperative chemotherapy and those receiving adjuvant chemotherapy had no statistical significance (P > 0.05). However, in the group that had normal serum CEA, patients receiving perioperative chemotherapy had a longer survival time. In multivariate analysis, T staging and lymph node metastatic rate were independent prognostic factors for the patients. Perioperative chemotherapy improved the overall survival of patients who had a normal pretreatment CEA level (P = 0.070).

CONCLUSION: Normal pretreatment serum CEA is a predictor of survival for patients receiving perioperative chemotherapy.

Keywords: Carcinoembryonic antigen, Perioperative chemotherapy, Prognosis, Gastric adenocarcinoma, Survival